Collectively, our data indicated that N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl), a benzamide compound, named as MKI-1, was a new candidate MASTL inhibitor in breast cancer cells. Here, MASTL is linked to breast cancer.